A detailed history of Sherbrooke Park Advisers LLC transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 29,342 shares of PCRX stock, worth $581,851. This represents 0.1% of its overall portfolio holdings.

Number of Shares
29,342
Previous 16,337 79.6%
Holding current value
$581,851
Previous $467 Million 5.52%
% of portfolio
0.1%
Previous 0.08%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$11.7 - $28.46 $152,158 - $370,122
13,005 Added 79.6%
29,342 $442 Million
Q2 2024

Aug 14, 2024

BUY
$25.5 - $31.51 $416,593 - $514,778
16,337 New
16,337 $467 Million
Q3 2023

Nov 14, 2023

BUY
$30.68 - $40.09 $274,616 - $358,845
8,951 New
8,951 $275 Million

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $909M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Sherbrooke Park Advisers LLC Portfolio

Follow Sherbrooke Park Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sherbrooke Park Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sherbrooke Park Advisers LLC with notifications on news.